1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Animalcare Group PLC

Animalcare Group PLC

LLSE:ANCR
335.00
GBX
+1.50
(+0.45%)
16.36BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.62
0.65
0.7
- -
- -
1.21
1.18
1.17
1.23
1.19
1.18
1.21
1.29
- -
Basic EPS, GAAP
0.1
0.12
0.13
- -
- -
-0.02
-0.02
- -
- -
0.03
0.02
0.3
0.07
- -
Free Cash Flow per Basic Share
0.04
0.15
0.12
- -
- -
0.04
0.18
0.14
0.18
0.11
0.14
0.14
0.11
- -
Dividend per Share
0.05
0.06
0.06
- -
- -
0.04
0.04
0.02
0.04
0.04
0.04
0.05
0.05
- -
Book Value per Share
0.93
1
1.07
- -
- -
1.44
1.36
1.36
1.31
1.31
1.3
1.64
1.66
1.66
Tangible Book Value per Share
0.26
0.31
0.32
- -
- -
-0.26
-0.19
-0.12
-0.03
0.05
0.11
0.83
-0.03
-0.03
Basic Weighted Avg Shares
21
21
21
21
42
60
60
60
60
60
60
61
69
69
Sales/Revenue/Turnover
13
14
15
- -
- -
72
71
70
74
72
71
74
89
- -
Operating Margin (%)
20.83
22.98
21.7
- -
- -
4.83
4.98
3.94
6.4
5.79
5.68
9.54
6.96
- -
Depreciation Expense
- -
- -
- -
- -
- -
8
9
9
8
8
8
7
9
- -
Net Income, GAAP
2
3
3
- -
- -
-1
-1
- -
- -
2
1
18
5
- -
Effective Tax Rate (%)
20.02
15.81
14.65
- -
- -
- -
- -
- -
108.15
22.7
66.6
16.7
19.94
- -
Profit Margin (%)
16.59
18.72
17.92
- -
- -
-1.37
-1.88
0.33
-0.1
2.74
1.7
24.92
5.7
- -
Working Capital
6
7
8
- -
- -
19
13
10
10
12
11
77
13
13
LT Debt
- -
- -
- -
- -
- -
31
23
17
10
11
5
21
12
12
Total Equity
19
21
23
- -
- -
87
82
82
79
79
78
113
115
115
Return on Invested Capital (%)
11.08
12.12
11.53
- -
- -
- -
- -
- -
-0.17
2.73
1.5
5.24
3.6
- -
Return on Capital (%)
11.42
12.53
12.11
- -
- -
- -
- -
- -
-0.12
2.67
1.66
17.1
4.35
- -
Return on Common Equity (%)
11.42
12.53
12.11
- -
- -
- -
-1.59
0.29
-0.1
2.49
1.53
19.34
4.46
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
2
3
3
LT Borrowings
20
16
10
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
168
203
164

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
98
42
34
Cash, Cash Equivalents & STI
12
10
3
Accounts Receivable, Net
14
15
16
Inventories
12
14
13
Total Current Liabilities
21
22
21
Payables & Accruals
- -
- -
- -
ST Debt
2
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.4%
1.08%
Free Cash Flow
- -
0.78%
-9.35%
Net Income, GAAP
- -
-290.79%
-72.54%
Sales/Revenue/Turnover
- -
5.1%
20.04%
Total Cash Common Dividend
- -
- -
18.81%

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
71
2024
- -
- -
74
2025
- -
- -
89

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.02
2024
- -
- -
0.3
2025
- -
- -
0.07

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.04
2024
- -
- -
0.05
2025
- -
- -
0.05

Company Description

Company Profile APIChatGPT
CEO
Jennifer Ann Julia Winter
Full Time Employees
220
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Moorside York NY United Kingdom YO32 9LB
IPO Date
Jan 15, 2008
Website
animalcaregroup.co.uk
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Animalcare Group plc is an international veterinary sales and marketing company that develops, commercializes and distributes prescription and over-the-counter pharmaceutical products, identification services and related offerings to improve animal health and wellbeing for companion animals, production animals and equine markets. The company offers a focused portfolio of high-margin brands including Daxocox, a long-acting COX-2 inhibitor NSAID for chronic osteoarthritic pain in dogs; Plaqtiv+, a biofilm-targeting dental care range; Orozyme dental hygiene products; Danilon, an anti-inflammatory treatment for equine; fluids and other equine therapeutics; dermatological treatments via partnerships such as Yun Probiotherapy; production animal pharmaceuticals with emphasis in southern Europe; and microchipping and companion animal identification services. It operates through direct commercial presence in seven European countries including the UK, Belgium, France and others, exports to more than 40 markets worldwide, and following the January 2025 completion of its transformational acquisition of Randlab Australia Pty Ltd and subsidiaries for approximately £60m, now maintains operations in Australia and New Zealand to strengthen its equine portfolio and enable expansion into Asia Pacific. Founded in 1972 and headquartered in York, United Kingdom, Animalcare Group plc lists on the UK AIM exchange (ANCR.L) and pursues growth via its development pipeline, in-licensing, partnerships and acquisitions.